Abstract: This invention relates to the use of compounds of formula I
wherein R1, R2, R3, X, m and n are defined as in the specification, and their pharmaceutically acceptable salts, for the treatment of disorders of the serotonin system.
Abstract: Antipsychotic compounds having the formula ##STR1## wherein R is hydrogen, acyl or substituted acyl; and a pharmaceutically acceptable acid addition salt thereof.
Type:
Grant
Filed:
March 24, 1994
Date of Patent:
October 15, 1996
Assignee:
Pfizer Inc.
Inventors:
Gene M. Bright, Kishor A. Desai, Thomas F. Seeger, Teresa A. Smolarek
Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
Type:
Application
Filed:
December 5, 2001
Publication date:
July 18, 2002
Applicant:
Pfizer Inc
Inventors:
Phillip Branch Chappell, Stevin Howard Zorn
Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
Type:
Application
Filed:
September 3, 2003
Publication date:
March 11, 2004
Applicant:
Pfizer Inc
Inventors:
Phillip Branch Chappell, Stevin Howard Zorn
Abstract: The instant invention is directed to compounds, compositions and antipsychotic methods of use wherein the compounds are of formula I: ##STR1## wherein Y is an imide or benzoyl alkyl group and X is a cycloalkyl, phenyl or dibenzoazepinyl group.
Abstract: The invention relates to novel pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to formulations of varenicline wherein the dosage forms that are produced therefrom generate under specified storage conditions less than about 4% on a weight basis of the N-formyl and N-methyl degradation products.
Abstract: A compound of the formula
wherein m, R1, R2, R3, R4, R5 and X are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.
Abstract: The invention provides compounds of the formula: ##STR1## The variables are defined in the specification. The compounds are useful e.g. for the curative or prophylactic treatment of allergic conditions.
Abstract: Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein x is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.
Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.
Type:
Application
Filed:
August 4, 2009
Publication date:
June 16, 2011
Applicant:
PFIZER INC
Inventors:
John Frederick Braganza, Michael Raymond Collins, John Charles Kath, Sacha Ninkovic, Hui Li, Daniel Tyler Richter
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
Type:
Application
Filed:
October 31, 2013
Publication date:
February 27, 2014
Applicant:
Pfizer Inc.
Inventors:
Usa Reilly, Michael Joseph Melnick, Matthew Frank Brown, Mark Stephen Plummer, Justin Ian Montgomery, Ye Che, Loren Michael Price
Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
Type:
Application
Filed:
April 4, 2012
Publication date:
October 11, 2012
Applicant:
PFIZER LIMITED
Inventors:
Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
Type:
Grant
Filed:
March 27, 2012
Date of Patent:
August 19, 2014
Assignee:
Pfizer Inc.
Inventors:
Matthew Frank Brown, Jinshan Michael Chen, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
Abstract: A compound of the formula wherein D, E, F, G, L, T, W, X, Y, Z, U, A, R1, R2, R3, R4, R5, R6 R7 are as defined in the specification, pharmaceutical compositions thereof, and methods of use to treat diseases and as D3 receptor modulators.
Abstract: Racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals are useful in the treatment of abuse of and/or addiction to such substances as narcotics, alcohol and nicotine.
Abstract: This invention relates to the use of a compound of the formula
wherein m, R1, R2, R3, R4, R5 and X are as defined in the disclosure, for treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.
Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder, such as pathological gambling, attention deficit disorder with hyperactivity disorder and sex addiction, comprising administering a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 26, 2001
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc
Inventors:
Stevin H. Zorn, Mark A. Sanner, Antor F. Fliri, Patricia A. Seymour
Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
Type:
Application
Filed:
August 26, 2014
Publication date:
December 11, 2014
Applicant:
PFIZER LIMITED
Inventors:
Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
Abstract: A digitally trunked radio repeater system provides substantial improvements in timeliness of channel acquisition and channel drop, and in reliability of critical control signalling. The system uses a much higher digital signalling rate than is typically found in prior art systems, and uses a control channel to convey digital channel request and assignment messages between the central site and mobile transceivers. The mobile radio transceivers transmit channel requests on the control channel (if no response is received, the mobile retries during a retry time window which increases in duration in dependence on the number of retries). The mobile transceiver switches to a working channel in response to an assignement message received on the control channel. Subaudible digital signals transmitted on the control channel and on active working channels allow late entry, shifting to higher priority calls, and other advanced functions.
Type:
Grant
Filed:
January 3, 1990
Date of Patent:
June 23, 1992
Assignee:
Ericsson GE Mobile Communications Inc.
Inventors:
Jeffrey S. Childress, Marc A. Dissosway, Gerald M. Cooper, Houston H. Hughes, III